News | 53Biologics

Aseptic fill and finish grade A isolator in GMP cleanroom environment at 53Biologics

March 11, 2026 Patricia De La Madrid Comments: 0

Understanding the Manufacturing Responsibilities for Drug Substances and Drug Products

Understanding the responsibilities involved in Drug Substance and Drug Product manufacturing is essential for making the right strategic decisions. Many biotech companies approaching clinical phases discover that the distinction between these two stages affects regulatory compliance, timelines, and manufacturing partnerships. Working with an experienced CDMO is often the most efficient way to manage these responsibilities while maintaining compliance with international regulatory standards. Drug...

February 24, 2026 Patricia De La Madrid Comments: 0

GMP Manufacturing Pitfalls That Delay Biologics Production (and How to Avoid Them)

GMP manufacturing pitfalls that delay biologics production can increase costs, disrupt clinical timelines, and compromise regulatory readiness if not addressed early. In biologics development, delays rarely come from a single dramatic failure. More often, they result from small oversights during process development that later become major bottlenecks under GMP conditions. Whether you are working with microbial or mammalian systems, understanding common GMP manufacturing pitfalls is essential to...

Tangential flow filtration system for protein concentration CDMO GMP manufacturing

February 10, 2026 Patricia De La Madrid Comments: 0

From Development to GMP Manufacturing: When Should You Engage a CDMO?

In biologics development, timing is everything. Engaging a CDMO too late can lead to delays, regulatory gaps, and costly process redesigns. Engaging too early, without a clear development strategy, can slow momentum and inflate budgets. So when is the right moment to bring a CDMO into your program? For companies moving from early development toward clinical manufacturing, this decision often determines how smoothly the transition to GMP manufacturing will unfold. At 53Biologics, we frequently wo...

January 27, 2026 Patricia De La Madrid Comments: 0

GMP Manufacturing with a Biologics CDMO: How to Make the Right Decision at a Critical Stage

Reaching the point where GMP manufacturing becomes a real requirement is a defining milestone for any biologics program. At this stage, development decisions are no longer theoretical. They directly affect regulatory outcomes, clinical timelines, manufacturing costs and long-term scalability. For many biotech companies, selecting the right CDMO is the single most important decision in the transition from development to clinical manufacturing. As a biologics CDMO specialized in GMP manufacturing,...

January 13, 2026 Patricia De La Madrid Comments: 0

Process Validation: The Hidden Key to Operational Excellence in Industry

Process validation ensures manufacturing consistency, reduces deviations, prevents rework, improves resource utilization, and facilitates production scale-up. As a direct result, it accelerates time to market. For many years, process validation has been viewed by management teams as a costly formality, a box to tick to comply with regulations. A kind of “necessary evil” more closely associated with regulatory compliance than with real business value. However, this perception is becoming outd...

November 21, 2025 Patricia De La Madrid Comments: 0

53Biologics, Valladolid SME of the Year 2025

The jury, made up of representatives from the Valladolid Chamber of Commerce, the Spanish Chamber of Commerce, Banco Santander, the Provincial Council of Valladolid and El Norte de Castilla, has recognised 53Biologics’ achievements in job creation, employee training initiatives, investment in technology, and the implementation of strong Corporate Social Responsibility policies, awarding the company the Valladolid SME of the Year 2025 prize. The company 53Biologics (Biotechnology Development fo...

October 28, 2025 Patricia De La Madrid Comments: 0

Project Management in Biologics Development: Keys to Successful CDMO Collaboration

Biologics development is complex. Each project involves multiple stakeholders, tight timelines and strict regulatory standards. For companies working with a Contract Development and Manufacturing Organization (CDMO), strong project management is the key to transform complexity into clarity. Without it, delays, cost overruns and miscommunication can easily derail progress. 1. Why Project Management Matters A biologics program spans many stages: cell line development, process optimization, scale-u...

October 17, 2025 Patricia De La Madrid Comments: 0

53Biologics featured in APTE Technonews for its innovation in RNA enzyme production

53Biologics has been featured in the latest edition of APTE Technonews (Issue 91), the magazine of the Spanish Association of Science and Technology Parks. The article highlights our contribution to innovation in RNA enzyme manufacturing. This is a cornerstone technology enabling mRNA vaccines, gene therapy and next-generation RNA-based treatments. The challenge of RNA enzyme manufacturing RNA-based therapeutics rely on high-performance enzymes such as RNA polymerase, essential for accurate RNA...

October 7, 2025 Patricia De La Madrid Comments: 0

Overcoming Bottlenecks in Downstream Processing

In biologics manufacturing, upstream production often captures much of the spotlight. Fermentation, cell culture and expression systems are frequently discussed as the heart of drug development. Yet, for many companies, the true bottleneck lies downstream, in purification. Chromatography and filtration steps that work well at bench scale can become major hurdles when scaled to industrial volumes. At 53Biologics, we understand that downstream processing is where efficiency, cost control and produ...

September 25, 2025 Patricia De La Madrid Comments: 0

Critical Quality Attributes (CQAs) in Biologics Manufacturing: Why They Matter

When it comes to biologics, quality is not just important, it is everything. Unlike small molecules, biologics are produced by living systems, which makes them more complex, more variable and more sensitive to manufacturing conditions. To ensure safety and efficacy, regulators require companies to define and monitor Critical Quality Attributes (CQAs) throughout development and production. At 53Biologics, we see CQAs as the blueprint of product quality. By identifying them early and controlling t...